[Federal Register Volume 66, Number 136 (Monday, July 16, 2001)]
[Notices]
[Pages 37040-37041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-17751]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Susan S. 
Rucker, J.D., at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-
mail: [email protected]. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications.

Interaction of AAV4 With Sialic Acid

JA Chiorini (NIDCR)
    Serial No. E-131-01/0 filed Mar 28, 2001.
    This patent application describes the ability of AAV4 (adeno-
associated virus, serotype 4) to interact with particular alpha 2,3-
linked sialic acid residues on susceptible cells. The 2,3-linked sialic 
acid residues constitute part of the cell surface receptor(s) for AAV4. 
The identification of these residues provides

[[Page 37041]]

a means of identifying host cells which may be particularly suited as 
targets for gene therapy using AAV4-based vector systems. In addition, 
the identification of this interaction permits the development of new 
means of purifying AAV4 viral particles.
    This work will be published, in part, at Kaludov, N. et al., J. 
Virol. (2001), in press.

Interaction of AAV5 With Sialic Acid

JA Chiorini (NIDCR)
    Serial No. E-145-01/0 filed Mar 28, 2001.
    This patent application describes the ability of AAV5 (adeno-
associated virus, serotype 5) to interact with particular alpha 2,3-
linked sialic acid residues on cells. These 2,3-linked sialic acid 
residues are part of the cell surface receptor(s) for AAV5. The 
identification of these residues as part of the AAV5 receptor, or 
receptor complex, provides a means of identifying host cells that may 
be particularly suited as targets for gene therapy using AAV5-based 
vector systems. In addition, the identification of this interaction 
permits the development of new means of purifying AAV5 viral particles.
    This work has been published, in part, at Walters, RW et al., JBC 
276 (No. 23) 20610-16 (June 8, 2001), and Kaludov, N. et al., J. Virol. 
(2001), in press.

Use of Activity Dependent Neurotrophic Factor Derived Peptides for 
Enhancing Learning and Memory

DE Brenneman and Catherine Spong (NICHD), Ilana Gozes (Tel Aviv 
University)Serial No/Ref: No.: E-147-96/8 (PCT) filed May 31, 2001 
which claims priority to 60/267,805 (E-147-96/6) filed February 8, 2001 
and 60/208,944 (E-147-96/5) filed May 31, 2000.
    These application(s) disclose the use of ADNF polypeptides, ADNF 
and ADNF III/ADNP or the ADNF derived peptides SAL (SALLRSIPA) and NAP 
(NAPVSIPQ) to improve learning and memory. The peptides SAL and NAP are 
preferred because of their ability to cross the blood-brain barrier and 
for their ease of synthesis. The peptides, when given alone or in 
combination, either in utero or post-natally, improve performance 
related to learning and memory. Combinations of NAP and SAL are 
preferred for prenatal administration. NAP alone is preferred for post-
natal administration. The ability to improve learning and memory when 
given in utero makes them attractive as candidates for the development 
of therapeutics for prevention or treatment of Down's Syndrome or 
Fragile X syndrome or other conditions associated with mental 
retardation. The ability to improve performance related to learning and 
memory in adults makes them attractive candidates for the development 
of therapeutics for Alzheimer's disease as well as Down's Syndrome or 
other conditions associated with mental retardation.
    This work has been published, in part, at Gozes I, et al. 
``Activity-dependent neurotrophic factor: intranasal administration of 
femtomolar-acting peptides improve performance in a water maze'' J 
Pharmacol Exp Ther, 293(3):1091-8 (Jun 2000).

    Dated: July 6, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-17751 Filed 7-13-01; 8:45 am]
BILLING CODE 4140-01-P